Moore Capital Management’s AstraZeneca AZN Stock Holding History

Moore Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-25,000	Closed	-$3.39M	–	447
2023 Q3	$3.39M	Buy	+25,000	New	+$3.41M	0.06%	205
2022 Q1	–	Sell	-205,822	Closed	-$24M	–	752
2021 Q4	$24M	Buy	+205,822	New	+$24.2M	0.48%	40
2014 Q4	–	Sell	-30,000	Closed	-$2.14M	–	313
2014 Q3	$2.14M	Sell	30,000 -10,000	-25%	-$732K	0.05%	282
2014 Q2	$2.97M	Buy	+40,000	New	+$2.89M	0.07%	247

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Moore Capital Management's AZN Position: Q4 2023 in Review

Moore Capital Management sold out of AstraZeneca (AZN) in Q4 2023, closing a stake of 25,000 shares — an estimated $3.39M sold.

Moore Capital Management first reported a position in AZN in Q2 2014 and held it in 4 quarters. The position peaked at $24M in Q4 2021. 1,130 funds tracked by Wall St. Rank hold AZN as of Q4 2023.

Moore Capital Management reported no remaining AstraZeneca position as of Q4 2023 after selling out during the quarter.
Moore Capital Management sold 25,000 AstraZeneca shares in Q4 2023, an estimated $3.39M.
Moore Capital Management first reported a position in AstraZeneca in Q2 2014 and held it in 4 quarters.
Moore Capital Management's AstraZeneca position peaked at $24M in Q4 2021.
1,130 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2023.

Based on Moore Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.